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Abstract Nasopharyngeal carcinoma (NPC), one of the
most common cancers in population with Chinese or Asian
progeny, poses a serious health problem for southern
China. It is unfortunate that most NPC victims have had
lymph node metastasis (LNM) when ﬁrst diagnosed. We
believe that the 2D based serum proteome analysis can be
useful in discovering new biomarkers that may aid in the
diagnosis and therapy of NPC patients. To ﬁlter the tumor
speciﬁc antigen markers of NPC, sera from 42 healthy
volunteers, 27 non-LNM NPC patients and 37 LNM NPC
patients were selected for screening study using 2D com-
bined with MS. Pretreatment strategy, including sonication,
albumin and immunoglobulin G (IgG) depletion, was
adopted for screening differentially expressed proteins of
low abundance in serum. By 2D image analysis and
MALDI-TOF-MS identiﬁcation, twenty-three protein spots
were differentially expressed. Three of them were further
validated in the sera using enzyme-linked immunosorbent
assay (ELISA). Our research demonstrates that HSP70,
sICAM-1 and SAA, conﬁrmed with ELISA at sera and
immunohistochemistry, are potential NPC metastasis-spe-
ciﬁc serum biomarkers which may be of great underlying
signiﬁcance in clinical detection and management of NPC.
Keywords Nasopharyngeal carcinoma 
Serum proteome  Carcinogenesis  Lymph node metastasis
Abbreviations
NPC Nasopharyngeal carcinoma
2D Two-dimensional electorphoresis
MALDI-TOF-MS Matrix-assisted laser desorption/
ionization-time of ﬂight-mass
spectrometry
LNM Lymph node metastasis
ICAM-1 Intercellular adhesion molecular-1
HSP70 Heat shock protein 70
SAA Serum amyloid A1 protein
ELISA Enzyme-linked immunosorbent assay
IHC Immunohistochemistry
Introduction
Nasopharyngeal carcinoma (NPC) is a rare malignancy in
most parts of the world, though it is highly prevalent in
Southern Asia, where the incidence is about a 100-fold
higher than in other populations. It is one of the most
confusing, commonly misdiagnosed and poorly understood
diseases. Previous studies show that the cancer is
an Epstein-Barr virus-associated malignancy with a
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ology of NPC is thought to be associated with a complex
interaction of genetic, viral, environmental and dietary
factors. Thanks to the advancements in genomics, proteo-
mics and bioinformatics in recent decades, the etiology,
carcinogenesis and progression of the disease is better
understood. Research into these components may unravel
the pathways in NPC development and potentially decipher
the molecular characteristics of the malignancy [1, 2]. NPC
is an insidious tumor and is usually at the stage of metas-
tasis involving lymph nodes or other organs before it can
be found. Thus early and accurate diagnosis is very
important for therapy and prognosis of NPC patients.
Unfortunately, no effective method of accurately diagnos-
ing new-onset NPC is available now. We presume if
speciﬁc serum biomarkers associated with NPC metastasis
can be identiﬁed on the basis of advancements in genom-
ics, proteomics and bioinformatics, an approach to the
early detection and monitoring of NPC may be found.
2D comparative proteome analysis is a new technology
for the separation and identiﬁcation of disease-speciﬁc
proteins, and it has been applied successfully to screen
potential biomarkers for NPC in cell lines and tumor tis-
sues [3–8]. In our previous studies, we employed proteomic
techniques to study protein changes of CNE2, a poorly
differentiated squamous carcinoma cell line of human NPC
cells, induced by 12-O-Tetradecanoyl-phorbol-13-acetate
(TPA). It is likely that TPA promotes NPC in necessary
cooperation with EBV, or that it may function as an anti-
proliferative or differentiative revulsant in noninitiated
cells [4]. However, if a marker can be detected only in
surgical specimens, its clinical signiﬁcance is limited,
especially for early screening or diagnosis. Recently, Saeid
R. et al. reported their pioneering work on NPC serum
analysis by 2D without any pretreatment, revealing the
enhanced expression of relatively abundant proteins as
ceruloplasmin (CPL) [9]. In order to ﬁnd relatively low-
abundant serum proteins which may be more valuable in
predicting NPC progression, we pretreated serum with
sonication, albumin and IgG depletion before 2D analysis.
By comparing 2D image analyses for healthy volunteers,
non-LNM NPC and LNM NPC patients, we may identify
the differentially expressed proteins so that speciﬁc serum
biomarkers associated with NPC metastasis can be found.
Materials and methods
Subjects
Serum samples from 42 healthy volunteers and 64 NPC
patients were available for comparative proteomic analysis.
Samples from NPC patients were obtained before any
clinical treatment. All the patients had a nasopharyngeal
biopsy and NPC was conﬁrmed by two independent
pathologists unaware of the patient’s condition. Careful
medical examinations and CT scan determined non-LNM
cases and LNM cases in the NPC patients. Clinical data of
all the subjects for 2D and ELISA are shown in Table 1.I n
the screening study, serum samples from the same group
were pooled to smooth intrinsic individual differences and
enhance common characteristic traits only related to dis-
ease status [10], aliquoted, and stored at -80C before
analysis. In the validation study, 26 of the patients received
a mean of 17.8 months of follow-up (range, 6–22 months)
after radiotherapy and/or chemotherapy. Six of the fol-
lowed-up patients died of NPC, and the other survived the
follow-up period.
Depletion of high-abundance proteins
Sigma-Aldrich ProteoPrep
 Immunoafﬁnity Albumin and
IgG Depletion Kit was used for depletion of proteins,
albumin and IgGs, allowing visualization of co-migrating
proteins with albumin and IgG on a 2D gel and also higher
sample loads for improved visualization of lower abun-
dance proteins. A total of 30 ll of serum was diluted with
100 ll of equilibration buffer from the depletion kit
(Sigma) and sonicated using four ultrasonic bursts of 15 s
each. Between sonications, the samples were chilled on ice.
Then serum albumin and IgG was depleted according to the
manufacturer’s instructions. After collection of the bound
proteins, the majority ([95%) of the unbound proteins
were left in the depleted serum sample. Modiﬁed Bradford
assay was used to measure the protein concentrations of all
serum samples [11].
2D analysis
The Immobiline Dry strip (pH 4–7, length 17 cm, Bio-Rad)
was rehydrated with 600 mg protein in 350 ml rehydration
buffer containing 7 M urea, 2 M thiourea, 4% CHAPS,
65 mM DTT, 5 mM tributylphosphine, 1% IPG buffer and
0.002% bromophenol blue for 14 h at room temperature.
IEF was performed using Protean IEF cell (Bio-Rad,
Hercules, CA, USA) with a total of 70 kVh. Then the strip
was subjected to two-step equilibration in equilibration
buffer containing 6 M urea, 30% glycerol, 2% SDS and
50 mM Tris–HCl (pH 6.8) with 1% w/v DTT for the ﬁrst
step, and 2.5% w/v iodoacetamide for the second step. The
second-dimensional SDS-PAGE gel (13% T, 2.7% C, and
20 9 20 9 1m m
3) was carried out using a Protean II xi
2D cell (Bio-Rad) according to the following procedure:
30 min at a constant current of 12 mA followed by 24 mA
per gel until the bromophenol blue front reached the
bottom of the gel. Subsequently the gels were stained with
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123MS accommodated silver staining [12]. 2D of each sample
was run in triplicate to minimize run-to-run variation. The
silver-stained 2D gel were scanned using a Power-Look
1100 imaging scanner (Umax, Dallas, TX, USA) and
analyzed using PDQuest 7.1 software package (Bio-Rad).
In-gel enzymatic digestion
Protein spots were excised from gel with an operating knife
blade, destained twice with 30 mM potassium ferricyanide
and 100 mM sodium thiosulfate (1:1 v/v) and then equili-
brated in 50 mM NH4HCO3 to pH 8.0. After dehydrating
with ACN and drying in N2 at 37C for 20 min, the gel
pieces were rehydrated in 15 ml trypsin solution (10 lg/ml
in 25 mM NH4HCO3)a t4 C for 30 min and incubated at
37C overnight. Peptides were extracted twice using 0.1%
TFA in 50% CAN and dried with N2.
MALDI-TOF-MS identiﬁcation
The peptide mixtures were solubilized with 0.5% TFA,
with saturated a-cyano-4-hydroxy-trans-cinnamic (CHCA)
solution in 0.1% TFA/50% acetonitrile as the matrix and
analyzed using M@LDI R (Micromass, Manchester, UK).
Mass spectra were externally calibrated with lock mass
2,465.199 Da and internally calibrated with autodigested
peaks of trypsin (MH+: 2,211.105 Da).
Protein identiﬁcation and database searching
Protein identiﬁcation using peptide mass ﬁngerprinting
(PMF) was performed by the MASCOT search engine
(http://www.matrixscience.com/, MatrixSicence Ltd.,
London, UK) against the MSDB protein database. The
errors in peptide masses were in the range of 25 ppm. One
missed tryptic cleavage site per peptide was allowed during
the search. Proteins matching more than four peptides and
with a MASCOT score higher than 64 were considered
signiﬁcant (P\0.05). Carboamidomethylation of cysteine
was selected as the static modiﬁcation and oxidation of
methionine as the differential modiﬁcation. Protein iden-
tiﬁcation results were ﬁltered with peakErazor software.
Enzyme-linked immunosorbent assay (ELISA)
conﬁrmation
ELISAs were conducted to conﬁrm the protein identiﬁca-
tion and differential expression of sICAM-1, SAA and
HSP70 in sera from the three groups. Measurements were
done by commercially available ELISA kits (StressXpress
Hsp70 ELISA Kit: EKS-700B, Stressgen Biotechnologies,
Victoria; High sensitivity sICAM-1 ELISA Kit: BMS241,
Bender Medsystems Company, Australian; Human SAA
ELISA Kit: EL10015, YES Biotech Laboratories Ltd,
Canada), in accordance with the manufacturer’s instruc-
tions. All sera were stored at -80C before they
were measured. Both standards and samples were run in
duplicate. The main protocols were as follows: monoclonal
coating antibody was adsorbed onto microwells; target
protein present in the sample or standard bound to anti-
bodies was adsorbed to the microwells; second antibody
was added and bound to target protein captured by the ﬁrst
antibody; following incubation unbound enzyme was
removed during a wash step; a color reaction was formed
and absorbance was measured at 450 nm. The standard
curve was used to determine the concentration of target
protein in an unknown sample.
Immunohistochemistry (IHC) assay
The previous studies showed that sICAM-1 in serum could
be released by membrane-associated ICAM-1 of cancer
cell [13, 14]. However, SAA is synthesized and secreted
into serum by hepatocytes in the liver during the acute
phase [15, 16]. In the present study, therefore, expressions
of only HSP70 and ICAM-1 were detected in tissue by IHC
assay. Three-micrometer sections of parafﬁn-embedded
tissues were cut for a prior antigen retrieval step in boiling
10 mM citrate buffer pH 6 for 20 min. The ﬁxed tissues
were subjected to immunostaining using an ultrasensitive
S-P technique (MaiXin, China). Brieﬂy, the slides were
incubated overnight at 4C with goat anti-ICAM and anti-
HSP70 polyclonal antibody (1:200) (Wuhan Boster Bio-
logical Technology Co., Ltd., China). The concentrations
of the primary antibodies used have been optimized pre-
viously. After washing with PBS three times, they were
Table 1 Serum samples in the study
Samples for 2-DE Samples for ELISA
Healthy NPC Healthy NPC
Lymph node status / Negative Positive / Negative Positive
Number 42 27 37 30 27 30
Gender (Male/Female) 22/20 21/6 23/14 15/15 21/6 20/10
Age (±SD) 42 ± 7.9 43 ± 10.9 50.5 ± 11.7 42.5 ± 8.9 43 ± 10.9 47.6 ± 10.2
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123treated with biotin-conjugated second antibody before
adding streptavidin-peroxidase. For color reaction, diam-
inobenzidine (DAB) was used. All series included positive
controls. For negative controls, the antibody was replaced
by PBS. To evaluate the expression, the cellular localiza-
tion of immunoreactivity was determined and scored for
both intensity (negative, weak, moderate and strong) and
proportion (5–25, 26–50, 51–75 and 76–100%) of stained
cells. To allow comparison of immunostaining with path-
ological stage and metastasis for each cancer, integer
values were assigned to the scores of intensity (0–3) and
proportion of tumor cells stained (0–4). If the evaluations
did not agree, the specimens were reevaluated and then
classiﬁed according to the assessments given, most fre-
quently, by the observers. The proportion and intensity
scores were then added to obtain a total score, which was
labeled as one of the four following categories: (a) high
positive (+++), total score of 6–7; (b) moderate positive
(++), total score of 4–5; (c) low positive (+), total score of
2–3; (d) negative (-), total score of 0–2.
Statistical analysis
All the analyses performed were descriptive. The serum
levels of protein expressions were compared using one-way
ANOVA test. Associations between immunohistochemical
scores and clinicopathological variables of tissue speci-
mens were evaluated by Fisher’s exact test or v
2 test.
PDQuest software was used to establish a master gel rep-
resenting each group [17]. For differential expression of
matched gels, protein spots whose intensities were either
increased or decreased two-fold or greater were marked
and then conﬁrmed by manual inspection of all relevant 2D
gel, not only those included in the matchsets, to ensure
consistency. Quantitative analysis was performed using the
Student’s t-test among three groups of gels. All statistical
analysis was performed with SPSS 10.0 software and
P value\0.05 were considered statistically signiﬁcant.
Results
Quantitative comparison and identiﬁcation of protein
spots on 2D gels
Among the three groups, we found twenty-three spots
signiﬁcantly altered (P\0.05) or absent/emergent, 13 of
which were identiﬁed successfully (Fig. 1). The corre-
sponding detailed differential expression patterns are
shown in Fig. 2a. Quantitative comparison and MS iden-
tiﬁcation of the 13 differentially expressed proteins are
shown in Fig. 2b and summarized in Table 2, respectively.
Overall, transferrin (TRF) and transthyretin (TTR) were
down-regulated and 12-lipoxygenase (12-LOX), serum
amyloid A1 protein precursor (SAA), soluble intercellular
adhesion molecule-1 (sICAM-1) and lysine-speciﬁc his-
tone demethylase1 (LSD1) were up-regulated in two NPC
groups compared with the healthy group. Furthermore,
increased expression levels of 12-LOX, sICAM-1 and SAA
were observed in LNM NPC as compared with non-LNM
NPC. However, heat shock protein 70 (HSP70) and cyto-
chrome P450 (CYP450) were expressed signiﬁcantly and
constantly only in LNM NPC patients. The MALDI-TOF-
MS mass spectra are shown in Fig. 3.
ELISA conﬁrmation
Figures 4 and 5 show the ELISA results of sICAM-1, SAA
and HSP70 performed in the three groups. There were
Fig. 1 Representative 2D patterns of albumin and IgG depleted
serum from healthy (a), non-LNM NPC (b) and LNM NPC groups
(c). In the 2D images, spots ‘1–10’ indicate up-regulation and ‘11–13’
down-regulation in NPC group. Black arrows indicate protein spots
that were identiﬁed successfully by MS
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123statistically signiﬁcant differences between health and NPC
groups (P\0.01) as well as between non-LNM and LNM
NPC groups (P\0.05) (Fig. 4). And with the TNM stage
advanced, the serum levels of sICAM-1 and HSP70, were
detected signiﬁcantly elevated, but that of SAA not (Fig. 5).
Furthermore, bivariate correlation analysis showed a signiﬁ-
cant relationship between the serum levels of the three
proteins (P\0.01). The follow-up showed that the serum
levelsofsICAM-1andHSP70,butnotofSAA,werestrongly
associated with NPC mortality (Student’s t-test, P =0 . 0 0 1 ,
0.001 and 0.132, respectively). Our ELISA ﬁndings were
consistent with results of 2D and silver-staining.
IHC assay
In NPC patients, HSP70 and ICAM-1 were observed
in tumor cells but not in stromal, endothelial or
inﬂammatory cells. The immunoreactivity was located in
both membrane and cytoplasm for ICAM-1 and only in
cytoplasm for HSP70 (Fig. 6). The immunoreactivities of
HSP70 and ICAM-1 were observed in 37 (64.9%) and
43 (75.4 %) of the 57 cases of NPC, respectively. The
correlation of positive rates showing HSP70 and ICAM-1
immunoreactivity with clinicpathological characteristics
of the cases is summarized in Table 3. Statistically,
positive expression rates of HSP70 and ICAM-1 were
signiﬁcantly correlated with lymph node metastasis
(LNM) of NPC. Furthermore, we found that positive
expression rates of ICAM-1 (6/6, 100%) and HSP70
(5/6, 83.3%) were high in the cases that died of
NPC during the follow-up period (P[0.05). The results
manifested that ICAM-1 and HSP70 expressions were
strongly associated with NPC metastasis and mortality,
indicating poor prognosis.
Fig. 2 Detailed 2D patterns of
the thirteen differentially
expressed proteins among
healthy, non-LNM and LNM
NPC groups (a). Corresponding
gel positions are shown in
Fig. 1. Magniﬁed 2D maps
demonstrating the different
expressions of selected proteins
are listed in Table 2. The
densitometric analysis of each
protein was calculated from
nine different gels using
PDQuest 7.1 software package
(b). Each bar represents the
mean ± S.D. of intensity, with
signiﬁcant differences between
groups found by two-tailed
student’s-test. Note that this
panel has a different vertical (y)
axis and a break in the axis to
accommodate the poor
performance of the subject spot
No.6. The break region is from
5000 to 6000. *P\0.05,
compared with healthy group;
**P\0.05, compared with
non-LNM NPC group
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Serum is a complex body ﬂuid, containing a large diversity
of proteins. More than 10,000 different proteins are present
in the human serum and many of them are secreted or shed
by cells during different physiology or pathology processes
[18]. Consequently, proteomics has raised great expecta-
tions for the discovery of biomarkers to improve diagnosis
or classiﬁcation of a wide range of diseases, including
cancers [19]. Serum is expected to be an excellent source of
protein biomarkers because it circulates through, or comes
in contact with, all tissues. During this contact it is likely to
pick up proteins secreted or shed by tissues, which has
recently been tested and conﬁrmed [20]. However, serum
has been termed as the most complex human proteome [21]
with considerable differences in the concentrations of
individual proteins, ranging from several milligrams to less
than one pictogram per milliliter [22]. Another analytical
challenge for biomarker discovery arises from the high
variability in the concentration and state of modiﬁcation of
some human plasma proteins between different individuals
[23].Despitetheselimitations,humanserumholdsimmense
diagnostic potential. In the last decade, several large-scale
projects have been initiated, aimed at characterizing the
human plasma/serum proteome.
In the mean time, several serum proteomic studies on
NPC have been reported. Cho et al. performed protein chip
proﬁling analysis with surface-enhanced laser desorption
ionization time-of-ﬂight mass spectrometry (SELDI-TOF-
MS) technology on sera from NPC patients and demon-
strated that SAA may be a potentially usefully biomarker
for NPC [24]. However, the technology for discovery of
new cancer biomarkers has recently been questioned for its
ﬂaws, such as its qualitative nature, high identiﬁcation
error rate, poor reproducibility and nonspeciﬁc absorption
matrices [25–27]. 2D-based comparative proteome analy-
sis, though a new technology for the separation and
identiﬁcation of disease-speciﬁc proteins, has been applied
successfully to screen potential biomarkers for NPC in cell
lines and tumor tissues [3–8].
Recently, Saeid et al. reported their pioneering work on
NPC serum analysis by 2D, revealing the enhanced
expression of such relatively abundant proteins as cerulo-
plasmin (CPL) [9]. However, in 2D study, abundant
proteins, such as albumin and IgG, that account for
approximately 60–97% of the total serum proteins [28],
mask other proteins that migrate to the surrounding areas
and limit the loading amount of serum. As albumin and
IgG are known to function as carriers and transporters of
important proteins such as hormones, cytokines, and lipo-
proteins within the blood [29–31], the depletion of these
two highly abundant proteins may result in the loss of
potentially important proteins bound to them at the same
time. In order to release those adsorbed or bound proteins,
Table 2 Identiﬁcation results of differentially expressed proteins among healthy volunteers, non-LNM NPC and LNM NPC patients
No.
a Protein description MSDB ID Protein
level
b
MASCOT
score
c
Sequence
coverage
d (%)
Theoretical
Mr/pI
e
1 Ovochymase precursor Q7RTY7 : 116 52 124,947/8.67
2 Arachidonate 12-lipoxygenase AAA51587 : 193 68 75,694/5.82
3 sICAM-1 Q99930 : 112 54 4270/6.40
4 Cytochrome P450 Q53EX9 : 207 57 55,635/6.83
5 Serum amyloid A1 protein precursor YLHUS : 170 85 13,524/6.28
6 Hemoglobin beta subunits are s-
nitrosylated
1BUWB : 207 55 15,565/6.76
7 E1A 10S protein Q9YLA2 : 143 69 28,493/4.09
8 Lysine-speciﬁc histone demethylase 1 O60341 : 172 58 93,358/6.11
9 KIAA1622 protein Q9HCF0 : 78 61 102,351/8.42
10 Heat shock 70 kDa protein (HSP70) Q6G1F9 : 157 53 68,161/4.88
11 Transferrin Q9NQB8 ; 167 67 77,050/6.81
12 UPF0366 protein C11orf67 AAD40378 ; 104 58 12,798/8.58
13 Transthyretin AAA61181 ; 87 69 12,836/5.35
a The numbers indicate the spot positions in 2D gel as shown in Figs. 1 and 2
b :, up-regulation in NPC patients; ;, down-regulation in NPC patients
c By MALDI-TOF MS analysis
d Calculated by amino acid count
e Calculated from the database entry without any processing
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123we sonicated the diluted sera before the depletion and
desalting steps as suggested by Quero et al. [32, 33]. The
improvements we made in sample preparation enabled us
to ﬁnd some valuable low abundant proteins.
Of the 13 successfully identiﬁed protein spots, we
focused on 10 up-regulated proteins in NPC for further
validation. We also accumulated certain knowledge about
three proteins by literature proﬁling. Finally, we decided to
further investigate sICAM-1, HSP70 and SAA, which
seemed more associated with our research interest, using
both ELISA and IHC to validate their differential expres-
sions. Intriguingly, most of these identiﬁed proteins have
been reported to be associated with carcinogenesis and
tumor metastasis. Our research is herein chieﬂy concerned
with the functional implications of the three proteins to
NPC at the serum level.
Although the source of sICAM-1 has not been fully
elucidated, researches show it can be released by cancer
Fig. 3 PMF of protein spots
No. 3, 5 and 10, respectively,
representing sICAM-1 (panel
A), SAA (panel B), and HSP70
(panel C), which were expressed
differentially between the
groups of non-LNM and LNM
NPC (MASCOT scores are 65,
85 and 78, respectively,
P\0.05)
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123cells [13, 14] as well as by peripheral blood mononuclear,
endothelial, and ﬁbroblastic cells [34]. Proteolytic cleavage
of membrane-bound ICAM-1 may be the most likely
mechanism for the generation of sICAM-1 [35]. In patients
with certain malignancies, the serum sICAM-1 titers have
been found elevated in association with tumor growth and
distant metastasis of malignant melanoma [36], lung [37],
breast [38], gastric [39], hepatocellular [40], and colorectal
cancers [41]. Poor survival of cancer patients correlated
with a high level of serum sICAM-1 has also been dem-
onstrated [36, 38, 39]. In our study, the positive expression
of tissue ICAM-1 and levels of serum sICAM-1 were
signiﬁcantly correlated to the presence, progression,
metastasis and mortality of NPC. sICAM-1 possesses most
of the necessary extracellular structures to retain the
functional activities of ICAM-1 [13, 35]. It has been
reported that ICAM-1 on the surface of cancer cells or
antigen presenting cells (i.e., macrophages) is a costimu-
latory factor that stabilizes T-cell receptor-mediated
binding between these cells and T lymphocytes [42].
sICAM-1 would work as an immunosuppressive agent by
blocking LFA-1 on T lymphocytes, thus rendering it less
available for binding with ICAM-1 on the surface of cancer
cells [43]. In this manner, the shedding of sICAM-1 may
speed up the metastatic process by escaping host immune
surveillance. This, probably, presents an additional poten-
tial mechanism accounting for high serum levels of
sICAM-1 in NPC patients who have metastasized via
hematogenous and lymphatic routes. As serum sICAM-1
may be useful for monitoring hematogenous metastasis,
measuring the serum sICAM-1 level might be potentially
signiﬁcant in clinic.
SAA is an acute-phase protein with various isoforms in
a molecular mass range of 11–14. In normal individuals,
SAA is produced by hepatocytes in the liver [16]. After
secreted into serum, it rapidly binds to high-density lipo-
protein, with 90% of the protein particles bound [15]. A
review of the literature shows that only a low level of SAA
can be found in the sera of healthy individuals, despite the
ubiquitous nature of SAA [44]. This is in sharp contrast to
the patients with neoplastic diseases, such as those with
renal [45] and colorectal [46] cancers, who showed dra-
matic elevation of serum SAA. The prognostic signiﬁcance
of SAA for other cancers has also been found by conven-
tional radioimmunoassay, in line with the ﬁndings of this
study [47]. Cho et al. demonstrated that SAA may be a
potentially usefully biomarker for NPC [24]. The report
fully conﬁrmed relatively huge concentrations of SAA in
serum (0.2–2 g/l) that are thousands of times higher than
classical cancer biomarkers (such as CEA, PSA, CA125,
etc.) originating from tumor cells. In a similar way, we
further conﬁrmed that serum SAA was much elevated in
NPC patients, particularly at the process of lymph node
metastases when compared with non-LNM patients.
However, such biomarkers (acute-phase reactants) are not
commonly considered as cancer-speciﬁc ones and expected
to be elevated in other malignant diseases or inﬂammatory
diseases as well [26, 27]. In previous reports, SAA was
found elevated in different malignancies, such as cancers of
kidney, colon and prostate, as well as in leukemias and
Fig. 4 Quantitative comparison of sICAM-1, HSP70 and SAA in
sera among healthy, non-LNM NPC and LNM NPC groups. Each bar
represents the mean ± S.D. of the concentration, with signiﬁcant
differences between groups found by one-way ANOVA test. Note that
this panel has a different vertical (y) axis and a break in the axis to
accommodate the poor performance of the subject SAA. The break
region is from 500 to 4500 lg/l. *P\0.05, compared with healthy
group; **P\0.05, compared with non-LNM NPC group
Fig. 5 Quantitative comparison of sICAM-1, HSP70 and SAA in
sera among NPC patients at different TNM stage. Each bar represents
the mean ± S.D. of the concentration, with signiﬁcant differences
between groups found by one-way ANOVA test. Note that this panel
has a different vertical (y) axis and a break in the axis to
accommodate the poor performance of the subject SAA. The break
region is from 600 to 2000 lg/l. *P\0.05, compared with NPC
patients at TNM stage I; **P\0.05, compared with NPC patients at
TNM stage II; ***P\0.05, compared with NPC patients at TNM
stage III
472 Clin Exp Metastasis (2008) 25:465–476
123lymphomas [24, 48]. Therefore, SAA may represent a
cancer epiphenomenon, unlikely to be of much clinical use
in diagnosing and monitoring cancer [49], but it will be
interesting to explore whether the rapid production of SAA
in the liver or the epithelia of different organs [50] may be
related to the stimulation by cytokines abundantly present
in the NPC cells. It is also meaningful to investigate how
SAA is produced at different stages of clinical manifesta-
tion in NPC patients.
HSP70 is the main protein produced during cellular
response to varied stresses, such as heat shock, ischemia/
reperfusion, and oxidative changes [51, 52]. Because
HSP70 confers cell protection against different stresses, it
has been hypothesized that it plays a protective role in
Fig. 6 Immunohistochemical detection of HSP70 and ICAM-1 in
NPC (Magniﬁcation 9200). The immunoreactivity was located in
both membrane and cytoplasmic stainings for ICAM-1 but only in
cytoplasmic staining for HSP70. The black arrows indicate the target
proteins stained in brown-yellow in the NPC nest. The red arrow in E
shows negative immunoreactivity of normal nasopharyngeal epithe-
lia. a, negative expression of HSP70; b and c, positive expressions of
HSP70; d, negative expression of ICAM-1; e and f, positive
expressions of ICAM-1; a, b, d and e, non-LNM NPC; C and F,
LNM NPC
Table 3 Characteristics of NPC patients dependent on ICAM-1 and HSP70 expressions
Characteristics Number ICAM-1 expression HSP70 expression
Negative Positive (%) P value Negative Positive (%) P value
Gender
Male 41 9 32 (78.0) 0.464 15 26 (63.4) 0.704
Female 16 5 11 (68.8) 5 11 (68.8)
Age
Mean (45.4)
\45 years 26 7 19 (73.1) 0.704 9 17 (65.4) 0.945
C45 years 31 7 24 (77.4) 11 20 (64.5)
Lymph node status
Positive 30 3 27 (90.0) 0.012 5 25 (83.3) 0.002
Negative 27 11 16 (59.3) 15 12 (44.4)
TNM stage
I + II 24 11 13 (54.2) 0.002 12 12 (50.0) 0.044
III + IV 33 3 30 (90.9) 8 25 (75.8)
Survival rate
Survival 20 6 14 (70) 0.280 6 14 (70) 1.000
Mortality 6 0 6 (100) 1 5 (83.3)
Note: Values in parentheses are percentages
Clin Exp Metastasis (2008) 25:465–476 473
123tumor growth in vivo [53, 54]. Indeed, HSP70 is overex-
pressed in human tumors of varied origins [55], such as
colorectal [56], breast [57, 58], prostate [59], liver [60]
cancers and melanoma [61]. LNM and poor survival of
cancer patients correlated with HSP70 overexpression has
also been documented [57, 58, 61–63]. It is suggested that
HSP70 is needed for in vivo tumor progression. In addition,
HSP70 may be released from tumor cells involving
involves both active secretion and passive release from
necrotic cells [64]. Physiological mechanisms include co-
secretion in exosomes of HSC70 with TRF and the active
HSP70 secretion by the nonclassical pathway employed by
cytokines [65]. Therefore, HSP70 is detectable in serum so
that it could potentially be used as a biomarker for diag-
nosis or disease classiﬁcation. Abe et al. reported that
HSP70 is a marker of prostate cancer, and may be used in
conjunction with PSA to identify patients with early-stage
prostate cancer [59]. However, to the best of our knowl-
edge, the association between serum level of HSP70 and
NPC status has not been reported. Since our ﬁndings
demonstrated that there was a modest association between
serum HSP70 level and NPC staging, the serum HSP70
level should not be considered as an independent prog-
nostic factor in NPC patients, although it might be a
prognostic predictor by univariate analysis. In short, serum
HSP70 may have an adjunctive clinical value in monitoring
tumor progression and evaluating prognosis in NPC
patients, though its clinical application as a major tumor
marker is limited.
In conclusion, our serum proteomic analysis, using a
comprehensive pretreatment strategy, provides a practical
and exemplary tool of screening progression-associated
serum proteins in NPC research. After comparing 2D
image analyses for healthy volunteers, non-LNM NPC and
LNM NPC patients, we successfully identiﬁed 13 differ-
entially expressed protein spots. We further explored the
differential expressions of three of the proteins, namely,
sICAM-1, HSP70 and SAA, by ELISA at serum and IHC at
tissue, though more work should be completed to pinpoint
the direct correlation between serum level of sICAM and
HSP70 and their expression level in the tissues. We suggest
that the three proteins may be potential serum biomarkers
which can serve as effective target points for early diag-
nosis and therapy of NPC patients, though further clinical
research should be done before the potential come true.
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